Lakefront Biotherapeutics NV has announced a significant milestone with its acceptance of a poster presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. This event, scheduled for December 12-15 in New Orleans, will feature data from ongoing Phase 1b studies of gamgertamig, a potential treatment for autoimmune cytopenias. The presentation underscores Lakefront's commitment to advancing innovative therapies in the pharmaceutical preparations sector.

The announcement is crucial for Lakefront Biotherapeutics, particularly as it aims to establish itself as a leader in developing treatments for autoimmune diseases, an area that currently faces considerable unmet medical needs. The data presented could significantly influence treatment protocols and options available for patients suffering from these conditions.

Lakefront Biotherapeutics NV, listed on both the Nasdaq and OTC exchanges under the ticker symbols LKFT and GLPGF, is a biotechnology company focused on creating differentiated medicines for serious diseases. The company is incorporated in Belgium and operates under the SIC classification of 2834, which pertains to pharmaceutical preparations. Recent filings indicate that the company has been actively engaging with investors and stakeholders, as seen in its recent 6-K filings.

According to the filing dated November 4, 2026, the press release attached as Exhibit 99.1 highlights the promising results from the Phase 1b studies of gamgertamig. The data suggest that the treatment may enable patients to retain remission after B cell reconstitution without the need for background therapy. This aligns with the concept of an "immune reset," which could revolutionize the management of autoimmune cytopenias.

Eric Hedrick, Chief Medical Officer of Lakefront, expressed enthusiasm about the upcoming presentation, stating, "It is exciting to explore the predictability of robust responses, and the potential for immune reset-type activity, in results from company-sponsored trials." This statement reflects the company's confidence in the efficacy of gamgertamig and its potential impact on clinical practice.

The presentation at the ASH Annual Meeting is set for December 13, 2026, during the session focused on disorders of platelet number or function. The data will be presented by Phil Choi, MBBS, PhD, and will detail the initial global clinical experience with gamgertamig in treating relapsed or refractory autoimmune cytopenias.

The findings from these studies may have a significant impact on patients, particularly those suffering from immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). ITP affects approximately 120,000 people in the U.S., while AIHA impacts around 40,000 to 50,000 individuals. Both conditions are characterized by the destruction of blood cells, leading to serious health complications.

Lakefront's commitment to advancing gamgertamig is further reinforced by its plans to hold an investor conference call on December 14, 2026, to discuss the results in detail. This call will provide an opportunity for investors to engage with the company's leadership and gain insights into the implications of the new data.

As Lakefront Biotherapeutics prepares for this pivotal moment, the pharmaceutical industry will be watching closely. The outcomes of the ASH presentation could influence not only the company's trajectory but also the competitive landscape within the pharmaceutical preparations sector. Other companies working on similar therapies may need to reassess their strategies in light of Lakefront's promising developments.

In summary, Lakefront Biotherapeutics' announcement of its upcoming presentation at the ASH Annual Meeting marks a significant step forward in its efforts to address critical needs in the treatment of autoimmune diseases. With the potential for gamgertamig to change clinical practice, the company is poised to make a meaningful impact in the pharmaceutical preparations industry.